Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering AG/Epix Contrast Agent Vasovist Gains EU Approval, Waits For FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Vasovist (formerly MS-235) has a U.S. user fee date of Nov. 23; FDA had requested efficacy data from new clinical trials.

You may also be interested in...



FDA Denies Epix Appeal, Asks For New Vasovist Trials

Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.

FDA Denies Epix Appeal, Asks For New Vasovist Trials

Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.

Epix Says FDA Will Take More Time to Review Vasovist Appeal

Company expects to hear a response to the appeal from agency in September.

Related Content

Topics

UsernamePublicRestriction

Register

PS061219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel